10 Best Diabetes Stocks To Buy According to Billionaires

5. AstraZeneca PLC (NASDAQ:AZN)

Number of Billionaires: 14

Dollar Value of Billionaire Holdings: $2,202,563,718

AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across various therapeutic areas, including diabetes. Its diabetes portfolio features innovative treatments such as SGLT2 inhibitors (e.g., FORXIGA), GLP-1 receptor agonists (e.g., Bydureon BCise), and DPP-4 inhibitors (e.g., Saxagliptin), aimed at managing blood sugar levels and offering additional health benefits like weight loss and reduced blood pressure. The company also develops combination therapies to enhance treatment convenience and efficacy, catering to a broad range of patients, from those in early diabetes stages to those with advanced cases and comorbidities.

AstraZeneca PLC (NASDAQ:AZN)’s Q4 2024 financial results highlight robust growth despite some challenges. Total revenue for the year increased by 21%, driven by strong performances across all therapy areas and geographies, particularly in emerging markets, which grew by 22%. This growth reflects rising demand for the company’s products and effective market penetration.

In terms of regional performance, China saw a slight decline in Q4 due to lower demand for respiratory products, although it grew by 11% for the year. Emerging markets overall showed strong growth. AstraZeneca PLC (NASDAQ:AZN)’s product sales grew by 19%, with alliance and collaboration revenues increasing by 55% and 54%, respectively, demonstrating strength in its portfolio and successful partnerships. High gross margins of 81.2% indicate strong pricing power and efficient cost management.

The company continued investing in research and development, with a 19% increase in R&D expenses, ensuring future growth and innovation. Despite an increase in net debt to $24.6 billion, the business’s financial position remains solid, with a consistent dividend payout of $3.10 per share appealing to investors seeking stable returns. As one of the best diabetes stocks, AstraZeneca PLC (NASDAQ:AZN) also made strides in diabetes care, with a positive Phase III trial for a new diabetes drug that further solidifies its presence in the market.